US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

16.77

-0.5900-3.40%

Post-market: 16.770.00000.00%16:04 EDT

Volume:12.87K

Turnover:217.62K

Market Cap:5.67B

PE:187.40

High:17.19

Open:16.72

Low:16.31

Close:17.36

Loading ...

Overview Company News Filings

ARTMS Drug Master File for Gallium Production Technology Referenced with Telix’s Gozellix®

Sector Update: Health Care Stocks Steady Premarket Friday

MT Newswires Live

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid Tariff Uncertainty, Lowered FedEx Outlook

MT Newswires Live

Telix Pharmaceuticals' New Drug Application for Prostate Imaging Drug Gets FDA Approval

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

Telix Pharmaceuticals Says US FDA Approves New Drug Application for Prostate Cancer Imaging Agent

MT Newswires Live

Telix Pharmaceuticals' Illuccix Approved in Brazil for Prostate Cancer Imaging; Forms Joint Venture With R2PHARMA

MT Newswires Live

Telix Pharmaceuticals Says Prostate Cancer Imaging Agent Approved in Brazil

MT Newswires Live

Telix Pharmaceuticals Expands into Latin America with Illuccix® Approval in Brazil

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

Wilsons Remains a Buy on Telix Pharmaceuticals Ltd. (TLPPF)

Telix Pharmaceuticals Adds Isotope Production Capability

MT Newswires Live

Telix Pharmaceuticals Announces Director’s Interest Change

Telix Pharmaceuticals Expands Theranostic Pipeline with FAP-targeting Acquisition

Telix Pharmaceuticals Announces Director’s Share Disposal

Grand Pharmaceutical Group Divests 45% of Telix Pharmaceuticals Shares

MT Newswires Live

Telix Pharmaceuticals to Showcase Radiotherapeutic Advances in Urologic Oncology

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

Telix Pharmaceuticals Executives Complete Major Share Sale

Telix Pharmaceuticals CEO, Co-Founder Sells Shares

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TLX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":16.77,"timestamp":1749240000000,"preClose":17.36,"halted":0,"volume":12873,"hourTrading":{"tag":"盘后","latestPrice":16.77,"preClose":16.77,"latestTime":"16:04 EDT","volume":34,"amount":578.18,"timestamp":1749240257024},"delay":0,"floatShares":275137421,"shares":338109048,"eps":0.089486,"marketStatus":"Market Closed","change":-0.59,"latestTime":"06-06 16:00:00 EDT","open":16.72,"high":17.1899,"low":16.31,"amount":217616.5022,"amplitude":0.050685,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.089486,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":17.36,"preHourTrading":{"tag":"盘前","latestPrice":17.03,"preClose":17.36,"latestTime":"09:28 EDT","volume":200,"amount":3406,"timestamp":1749216480030},"postHourTrading":{"tag":"盘后","latestPrice":16.77,"preClose":16.77,"latestTime":"16:04 EDT","volume":34,"amount":578.18,"timestamp":1749240257024},"volumeRatio":1.2461762087873647},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":275137421,"roa":"5.33%","roe":"13.92%","lyrEps":0.093266,"volumeRatio":1.2461762087873647,"shares":338109048,"dividePrice":0,"high":17.1899,"amplitude":0.050685,"preClose":17.36,"low":16.31,"week52Low":13.61,"pbRate":"15.37","psRate":"11.15","week52High":30.36,"institutionHeld":0,"latestPrice":16.77,"eps":0.089486,"divideRate":0,"volume":12873,"delay":0,"ttmEps":0.089486,"open":16.72,"prevYearClose":15.4,"prevWeekClose":16.9899,"prevMonthClose":16.9899,"prevQuarterClose":16.76,"fiveDayClose":16.9899,"twentyDayClose":17.05,"sixtyDayClose":17.16},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524119135","title":"ARTMS Drug Master File for Gallium Production Technology Referenced with Telix’s Gozellix®","url":"https://stock-news.laohu8.com/highlight/detail?id=2524119135","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524119135?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:49","pubTimestamp":1743511740,"startTime":"0","endTime":"0","summary":"BURNABY, British Columbia, April 01, 2025  -- Telix ARTMS, Inc. , a global leader in radioisotope production technologies, is pleased to announce that the drug master file 1 for gallium-68 production using its QUANTM Irradiation System  cyclotron technology has been referenced for the first time with a United States  Food and Drug Administration  approved product, with Gozellix .This approval will enable radiopharmacies and hospitals using ARTMS’ QIS cyclotron technology and associated targets to produce multi-Curies of 68Ga for use with Gozellix. The expanded distribution radius and increased dose production capacity, compared to existing gallium-based PET tracers, will facilitate broader and more equitable access. In addition, use of ARTMS’ technology is being expanded internationally where regulatory submissions are in preparation. Pharmaceutical companies will be able to reference ARTMS’ standardized isotope production technology with their approved drugs, helping to localize and s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/artms-drug-master-file-gallium-124900554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ASX","BK7039","TLX.AU","BK4139","BK7067","BK4543","DMF","SEC.AU","TLX","BK4141","BK4526","ASX.AU"],"gpt_icon":0},{"id":"2521281516","title":"Sector Update: Health Care Stocks Steady Premarket Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2521281516","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521281516?lang=en_us&edition=fundamental","pubTime":"2025-03-21 21:11","pubTimestamp":1742562696,"startTime":"0","endTime":"0","summary":"Health care stocks were steady premarket Friday as the iShares Biotechnology ETF  was inactive and the Health Care Select Sector SPDR Fund  was slightly lower recently.Alnylam Pharmaceuticals  shares rose past 4% after the company said the US Food and Drug Administration has approved the supplemental new drug application for its heart drug Amvuttra.Telix Pharmaceuticals  shares advanced nearly 4% after the company said the US Food and Drug Administration has approved its new drug application for Gozellix, a PSMA-PET imaging agent for prostate cancer.Dyne Therapeutics  appointed Erick Lucera as chief financial officer, effective March 31. Dyne Therapeutics shares were nearly 7% lower pre-bell.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DYN","BK4588","BK4548","BK4139","BK4581","BK7067","BK4505","TLX.AU","XLV","ALNY","BK4585","TLX","IBB"],"gpt_icon":0},{"id":"2521855132","title":"Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid Tariff Uncertainty, Lowered FedEx Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2521855132","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521855132?lang=en_us&edition=fundamental","pubTime":"2025-03-21 20:28","pubTimestamp":1742560125,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2% and the actively traded Invesco QQQ Trust (QQQ) retreated 0.3% in Friday's premarket activity, amid escalating tariff c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RTH","FDN","EQR","XLF","IYW","WKEY","RTH.AU","XSD",".IXIC","FDX","VIS","SLV","XRT","XLK","PMR","IYJ","EEM","FAZ","XLY","TLX","SOXX","XLE","BITO","IVV","EXI","UNG","IYE","TLX.AU","XLI","XLP","TD","IBB",".SPX","FAS","SPY.AU","IGV","SPY","XLV","IYH","USO","IGM","VHT.AU",".DJI","VHT","IPK","IYK"],"gpt_icon":1},{"id":"2521262401","title":"Telix Pharmaceuticals' New Drug Application for Prostate Imaging Drug Gets FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2521262401","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521262401?lang=en_us&edition=fundamental","pubTime":"2025-03-21 18:58","pubTimestamp":1742554680,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals' said its new drug application in the U.S. for an imaging agent received regulatory approval.The Melbrourne, Australia-based biopharmaceutical company said Friday that the Food and Drug Administration approved the new drug application for Gozellix.Gozellix helps with advanced imaging for prostate cancer, making it easier to detect. It provides a longer shelf life and an extended distribution radius compared to existing gallium-based imaging products, Telix said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Telix Pharmaceuticals' New Drug Application for Prostate Imaging Drug Gets FDA Approval","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX","BK7067","TLX.AU","BK4139"],"gpt_icon":0},{"id":"2521640957","title":"FDA Approves New Prostate Cancer Imaging Agent Gozellix®","url":"https://stock-news.laohu8.com/highlight/detail?id=2521640957","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521640957?lang=en_us&edition=fundamental","pubTime":"2025-03-21 18:30","pubTimestamp":1742553000,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, March  21, 2025  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/21/3046974/0/en/FDA-Approves-New-Prostate-Cancer-Imaging-Agent-Gozellix.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","EEA","ADT","BK4144","BK4139","BK4526","BK4528","BK4588","TLX","PSA","BK4533","BK4213","BK4217","BK4543","TGA","BK4165","BK4084","BK4192","BK4205","ASX","BK4233","UK","BK4141","DCP"],"gpt_icon":0},{"id":"2521159416","title":"Telix Pharmaceuticals Says US FDA Approves New Drug Application for Prostate Cancer Imaging Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2521159416","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521159416?lang=en_us&edition=fundamental","pubTime":"2025-03-21 08:15","pubTimestamp":1742516111,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said that the US Food and Drug Administration has approved its New Drug Application for Gozellix, the company's prostate-specific membrane antigen positron emission tomography  imaging agent for prostate cancer, according to a Friday filing with the Australian bourse.Gozellix is designed for PET scanning of PSMA-positive lesions in men with prostate cancer, the filing said.The agent offers a six-hour shelf life and extended distribution range compared to existing gallium-based imaging agents, improving access to PET scanners which currently cannot use other PSMA imaging products, filing added.Telix expects Gozellix to expand access by qualifying for full reimbursement with reduced or no patient co-insurance, which will benefit underserved populations.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","TLX","BK7067"],"gpt_icon":0},{"id":"2520244096","title":"Telix Pharmaceuticals' Illuccix Approved in Brazil for Prostate Cancer Imaging; Forms Joint Venture With R2PHARMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2520244096","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520244096?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:46","pubTimestamp":1742298364,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said late Monday that the Brazilian Health Regulatory Agency has approved the company's prostate cancer imaging agent, Illuccix.The company said the approval was granted to Telix's partner, R2PHARMA, and a subsidiary of Grupo GSH, which has been given an exclusive license to manufacture, distribute and market Illuccix in Brazil.Telix sadi it has formed a joint venture with R2PHARMA, named Telix Innovations Brazil, to commercialize and distribute Illuccix and other products from its pipeline in Brazil.Illuccix is already available in several countries, including Australia, Canada, New Zealand, the US, the UK, and various nations in the European Economic Area.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4185","BK7067","TLX","JYNT","TLX.AU","BK4139"],"gpt_icon":0},{"id":"2520638074","title":"Telix Pharmaceuticals Says Prostate Cancer Imaging Agent Approved in Brazil","url":"https://stock-news.laohu8.com/highlight/detail?id=2520638074","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520638074?lang=en_us&edition=fundamental","pubTime":"2025-03-18 07:32","pubTimestamp":1742254371,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) said the Brazilian Health Regulatory Agency approved its prostate cancer imaging agent Illuccix, according to a Tuesday Australian bourse filing.The marketing authoriza","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BDX.SI","BK7067","TLX.AU","XJO.AU","XAO.AU","TLX","BK6117","BK6505","BK4139"],"gpt_icon":0},{"id":"2520872936","title":"Telix Pharmaceuticals Expands into Latin America with Illuccix® Approval in Brazil","url":"https://stock-news.laohu8.com/highlight/detail?id=2520872936","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520872936?lang=en_us&edition=fundamental","pubTime":"2025-03-18 06:22","pubTimestamp":1742250148,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) has issued an update. Telix Pharmaceuticals has received approval from Brazil’s ANVISA for its prostate ca...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-expands-into-latin-america-with-illuccix-approval-in-brazil?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-expands-into-latin-america-with-illuccix-approval-in-brazil?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"gpt_icon":0},{"id":"2520842426","title":"Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America","url":"https://stock-news.laohu8.com/highlight/detail?id=2520842426","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520842426?lang=en_us&edition=fundamental","pubTime":"2025-03-18 05:53","pubTimestamp":1742248380,"startTime":"0","endTime":"0","summary":"MELBOURNE,Australia andPORTO ALEGRE,Brazil, March 18, 2025  -- Telix Pharmaceuticals Limited  today announces that the Brazilian Health Regulatory Agency  has approved Illuccix  the Company’s lead prostate cancer imaging agent. Illuccix is the first and only PSMA-PET1 prostate cancer imaging agent to receive full regulatory approval in Brazil.Illuccix, after radiolabeling with 68Ga, is a radioactive diagnostic agent indicated for positron emission tomography  of prostate-specific membrane antigen  positive lesions in men with prostate cancer:. With suspected metastasis who are candidates for definitive initial therapy treatment, and. With suspected recurrence based on an elevated specific antigen  level in the serum.PSMA-PET is a diagnostic technology demonstrated to detect advanced prostate cancer. ANVISA becomes the latest regulatory body worldwide to approve Illuccix3, which is already commercially available in Australia, Canada, New Zealand and the United States, and has recently b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/illuccix-approved-prostate-cancer-imaging-215300352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["PSA","TLX","BK4205","BK4084","XKO.AU","BK4526","SEC.AU","BK4141","BK4144","DCP","EEA","TGA.AU","ASX","UK","XAO.AU","BK4585","XJO.AU","ASX.AU","BK4192","BK4588","TLX.AU","BK4139","PET","BK7067","PET.AU","BK7039","BK7047","BK7001","BK4217","BK4233","BK4213","BK4528","BK4543","TGA","BK4533"],"gpt_icon":0},{"id":"2520324965","title":"Wilsons Remains a Buy on Telix Pharmaceuticals Ltd. (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520324965","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520324965?lang=en_us&edition=fundamental","pubTime":"2025-03-17 09:35","pubTimestamp":1742175310,"startTime":"0","endTime":"0","summary":"In a report released today, Shane Storey from Wilsons maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), with a price...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wilsons-remains-a-buy-on-telix-pharmaceuticals-ltd-tlppf-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wilsons-remains-a-buy-on-telix-pharmaceuticals-ltd-tlppf-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLPPF","TLX"],"gpt_icon":0},{"id":"2519004638","title":"Telix Pharmaceuticals Adds Isotope Production Capability","url":"https://stock-news.laohu8.com/highlight/detail?id=2519004638","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519004638?lang=en_us&edition=fundamental","pubTime":"2025-03-13 16:23","pubTimestamp":1741854229,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (TLX) said late Wednesday it completed the first production of lead-212 isotope using a new generator technology.The technology \"significantly\" increases the amount of radioactiv","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TLX","BK4139","TLX.AU"],"gpt_icon":0},{"id":"2518970645","title":"Telix Pharmaceuticals Announces Director’s Interest Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2518970645","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518970645?lang=en_us&edition=fundamental","pubTime":"2025-03-12 06:58","pubTimestamp":1741733914,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) has issued an announcement. Telix Pharmaceuticals Ltd. has announced a change in the director’s interest n...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-announces-directors-interest-change?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-announces-directors-interest-change?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"gpt_icon":0},{"id":"2518052867","title":"Telix Pharmaceuticals Expands Theranostic Pipeline with FAP-targeting Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2518052867","media":"TIPRANKS","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518052867?lang=en_us&edition=fundamental","pubTime":"2025-03-12 06:40","pubTimestamp":1741732839,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) has shared an announcement. Telix Pharmaceuticals Limited has completed the acquisition of FAP-targeting t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-expands-theranostic-pipeline-with-fap-targeting-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-expands-theranostic-pipeline-with-fap-targeting-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"gpt_icon":0},{"id":"2517798067","title":"Telix Pharmaceuticals Announces Director’s Share Disposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2517798067","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517798067?lang=en_us&edition=fundamental","pubTime":"2025-03-05 06:49","pubTimestamp":1741128586,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) has shared an update. Telix Pharmaceuticals Ltd. has announced a change in the director’s interest, specif...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-announces-directors-share-disposal?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-announces-directors-share-disposal?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"gpt_icon":0},{"id":"2516673406","title":"Grand Pharmaceutical Group Divests 45% of Telix Pharmaceuticals Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2516673406","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516673406?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:40","pubTimestamp":1741092057,"startTime":"0","endTime":"0","summary":"Grand Pharmaceutical Group  sold about 45.2% of its stake in Telix Pharmaceuticals  for AU$143 million in an off-the-market transaction, a Friday Hong Kong bourse filing said.The group will use proceeds from the disposal to fund its clinical development plans in areas of unmet need, including projects under its partnership with Telix.Grand Pharmaceutical Group plans not to sell the remaining stake it holds in Telix in the coming 12 months.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","BK7067","00512","TLX","BK1191"],"gpt_icon":0},{"id":"2516645196","title":"Telix Pharmaceuticals to Showcase Radiotherapeutic Advances in Urologic Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2516645196","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516645196?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:07","pubTimestamp":1741039622,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) has provided an update. Telix Pharmaceuticals Limited is hosting an investor webinar to showcase its late-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-to-showcase-radiotherapeutic-advances-in-urologic-oncology?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-to-showcase-radiotherapeutic-advances-in-urologic-oncology?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"gpt_icon":0},{"id":"2516669053","title":"Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2516669053","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516669053?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:48","pubTimestamp":1741038480,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, March  04, 2025  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3036083/0/en/Investor-Webinar-Telix-Therapeutics-Urology-Showcase-and-Expert-Forum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FET","BK4526","BK4543","BK4141","LENZ","ASX","TLX","BK4179","BK4139"],"gpt_icon":0},{"id":"2514816150","title":"Telix Pharmaceuticals Executives Complete Major Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2514816150","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514816150?lang=en_us&edition=fundamental","pubTime":"2025-02-27 09:39","pubTimestamp":1740620393,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) has shared an announcement. Telix Pharmaceuticals Limited announced the completion of a significant share ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-executives-complete-major-share-sale?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-executives-complete-major-share-sale?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"gpt_icon":0},{"id":"2514153088","title":"Telix Pharmaceuticals CEO, Co-Founder Sells Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2514153088","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514153088?lang=en_us&edition=fundamental","pubTime":"2025-02-27 09:26","pubTimestamp":1740619619,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  received notice that its Chief Executive Christian Behrenbruch sold 2 million shares in the company at AU$29.50 per share by way of a block trade, according to a Thursday Australian bourse filing.Behrenbruch now holds shares equal to about 6.3% of the company's issued capital and has no intention to sell them, the filing said.Additionally, the company's co-founder Andreas Kluge sold 2 million shares in the company for the same price.Company shares were down nearly 2% in recent Thursday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","TLX","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":119,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1749182400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2025-06-06","current":173.121803,"percent":0.388489,"low":151.061716,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"high":205.576265,"avg":177.817132,"sd":12.490541,"marketCap":5638091901.1},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1}],"updateTime":1749393308237}}}